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Background: The emergence of carbapenem resistance among gram-negative bacilli (GNB), 
mediated by carbapenemase production, has necessitated the development of a simple 
and accurate device for detecting minimum inhibitory concentrations (MICs) and resis-
tance mechanisms, especially carbapenemase production. We evaluated the performance 
of the BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) for anti-
microbial susceptibility testing (AST) and carbapenemase-producing organism (CPO) de-
tection.
Methods: We used 450 non-duplicate clinical GNB isolates from six general hospitals in 
Korea (409 Enterobacteriaceae and 41 glucose non-fermenting bacilli [GNFB] isolates). 
AST for meropenem, imipenem, ertapenem, ceftazidime, and ceftazidime/avibactam, and 
CPO detection were performed using the Phoenix NMIC-500 panel. Broth microdilution 
was used as the reference method for AST. The rates of categorical agreement (CA), es-
sential agreement (EA), minor error (mE), major error (ME), and very major error (VME) 
were calculated in each antimicrobial. In addition, PCR and sequencing were performed 
to evaluate the accuracy of CPO detection by the BD Phoenix NMIC-500 panel, and the 
rate of correct identification was calculated. 
Results: The CA rates were >90% for all antimicrobials tested with the Enterobacteria-
ceae isolates, except for imipenem (87.2%). The GNFB CA rates ranged from 92.7% to 
100% for all antimicrobials. The ME rates were 1.7% for Enterobacteriaceae and 0% for 
GNFB. The panel identified 97.2% (243/250) of the carbapenemase-producing isolates.
Conclusions: The BD Phoenix NMIC-500 panel shows promise for AST and CPO detection.
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INTRODUCTION
The global spread of carbapenemase-producing Enterobacteria-
ceae, P. aeruginosa, and Acinetobacter species is a critical medi-
cal and public health issue causing both nosocomial and com-
munity-acquired infections [1, 2]. Carbapenems are key antimi-
crobials in the clinical field, as they are considered the final line 
of defense against multidrug-resistant (MDR) gram-negative ba-
cilli (GNB) infections [3-5]. Resistance to carbapenems medi-
ated by the acquisition of carbapenemase production is increas-
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ingly reported [6]. Carbapenemese production by bacterial hosts 
induces resistance to nearly all β-lactam drugs and is associated 
with MDR phenotypes [7]. Therefore, the dissemination of car-
bapenemase-producing organisms (CPO) is considered a public 
health emergency in Korea, especially following outbreaks of 
Klebsiella pneumoniae carbapenemase-2 (KPC-2)-producing 
Klebsiella pneumoniae in 2011 and carbapenemase-producing 
carbapenem-resistant Acinetobacter baumannii in 2004 [8, 9]. 
The potential for further escalation of this scenario should not 
be ignored, as these genes are associated with mobile genetic 
elements, and the emergence of novel enzyme types and vari-
ants is expected [7]. Thus, rapid and accurate detection of anti-
microbial resistance and resistance mechanisms is important to 
prevent the dissemination of MDR bacteria [10].
Carbapenemases are usually classified into three classes of 
β-lactamases (according to their amino acid identity): Ambler 
class A (serine-β-lactamases), B (metallo-β-lactamases; MBLs), 
and D (oxacillinases; OXAs) β-lactamases. In addition, Ambler 
Class C β-lactamase (AmpC β-lactamase) could induce resistance 
to carbapenems in bacterial hosts, when accompanied with ad-
ditional resistance mechanisms such as porin loss [11-13].
Ceftazidime-avibactam was recently introduced as a new com-
pound combining ceftazidime and a novel β-lactamase inhibitor 
with activity against various β-lactamases produced by MDR GNB 
[14]. Avibactam was first reported in 2003; it is a β-lactamase 
inhibitor against Ambler class A and C β-lactamases, and this 
agent also possesses activity against some of Ambler class D 
enzymes [15, 16]. The addition of avibactam to ceftazidime im-
proves its in vitro activity against Enterobacteriaceae and Pseu-
domonas aeruginosa [17]. Recent study has revealed that cefta-
zidime-avibactam exhibits a good outcome to treat patients in-
fected with KPC-producing strains [18].
The BD Phoenix NMIC-500 panel (BD Diagnostic Systems, 
Sparks, MD, USA) has been designed with advantageous prop-
erties for determining carbapenem minimum inhibitory concen-
trations (MICs), as well as CPO detection, compared with a pre-
vious panel [GN-27 NMIC203 (BD Diagnostic Systems)] [19]. 
By including CPO detection and ceftazidime-avibactam MIC de-
termination in routine antimicrobial susceptibility testing (AST), 
the BD Phoenix NMIC-500 panel could offer valuable support 
for clinical studies examining different therapeutic strategies for 
infections caused by CPOs. To our knowledge, the performance 
of this panel has not been evaluated so far. We evaluated the 
performance of the BD Phoenix NMIC-500 panel for AST and 
CPO detection with clinical GNB isolates. 
METHODS
Bacterial strains
A total of 450 non-duplicate clinical GNB isolates collected from 
six general hospitals in Korea from May 2016 to April 2017 were 
used (409 Enterobacteriaceae isolates [225 K. pneumoniae, 133 
E. coli, 36 Enterobacter, nine Citrobacter freundii, five Raoultella, 
and one Klebsiella oxytoca isolates] and 41 glucose-non-ferment-
ing gram-negative bacilli [GNFB] isolates, including 21 P. aeru-
ginosa and 20 A. baumannii isolates). The isolates were inocu-
lated in a cryotube containing 20% (w/v) skimmed milk and 
stored at -80°C, and then transferred for the analysis; the per-
formance of the BD Phoenix NMIC-500 panel was evaluated at 
a single center from January 2018 to May 2018. This study was 
exempted from approval by the Ethics Committee on Human 
Research of the Health Ministry in Korea.
BD Phoenix analysis
AST was conducted according to the manufacturer’s instruc-
tions. Briefly, the identification (ID) broth was inoculated with 
bacterial colonies from pure cultures adjusted to 0.5–0.6 Mc-
Farland (McF) standard using a Phoenix spectrophotometric 
device. The standardized ID broth suspension (25 µL) were 
transferred to the Phoenix AST broth, which was supplemented 
with one drop of the Phoenix AST indicator for detecting organ-
ism growth before being added to the panels. The panels were 
sealed, logged, and loaded into the Phoenix device. The results 
were interpreted using Epicenter data management software 
version 7.22A (BD Diagnostic Systems) after 16 hours of incu-
bation.
Reference methods
The meropenem (range: 0.5–256 mg/L), imipenem (range: 0.5–
256 mg/L), ertapenem (range: 0.125–16 mg/L), ceftazidime 
(range: 0.125–16 mg/L), and ceftazidime-avibactam (range: 
0.125/4–8/4 mg/L) MICs of 450 GNB isolates were determined 
using the broth microdilution (BMD) method following the CLSI 
guidelines with Mueller-Hinton broth (Difco Laboratories, Detroit, 
MI, USA) [20]. E. coli ATCC 25922 and P. aeruginosa ATCC 
27853 were used as control strains, as recommended by the 
CLSI.
PCR and sequencing were performed for the carbapenem-re-
sistant GNB isolates to identify the carbapenemase genes includ-
ing KPC, New Delhi metallo-β-lactamase (NDM), imipenemase 
(IMP), Verona integron-borne metallo-β-lactamase (VIM), OXA-
48-like, and OXA-23. PCR was performed using the following 
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amplification conditions: 94°C for five minutes, followed by 30 
cycles of 94°C for 30 seconds, 58°C (KPC) or 60°C (OXA-48-
like, IMP, VIM, and NDM) for 30 seconds, and 72°C for 30 sec-
onds, followed by a final extension at 72°C for five minutes. To 
confirm the amplified products, they were directly sequenced 
using an automatic sequencer (model 3730xl; Applied Biosys-
tems, Weiterstadt, Germany). The oligonucleotide sequences of 
the primer used are summarized in Table 1.
Data analysis
The accuracy of the BD Phoenix NMIC-500 panel was calcu-
lated using categorical agreement (CA), essential agreement 
(EA), minor error (mE), major error (ME), and very major error 
(VME), which were determined by comparing its MIC results to 
the BMD results according to the CLSI breakpoints [21]. The 
Phoenix system results were considered CA if they agreed with 
the susceptible, intermediate, and resistant categories of the 
BMD results. Results were deemed EA when the MIC results 
using the BD Phoenix NMIC-500 panel and BMD were identical 
or 2-fold different. Results were deemed mE when one set of 
the AST results was intermediate while the other set was resis-
tant or susceptible. Results were deemed ME when the Phoenix 
system MIC results were resistant, while the BMD results were 
susceptible. Results were deemed VME when the Phoenix sys-
tem indicated susceptibility and the BMD indicated resistance.
The accuracy of CPO detection was determined as follows: 
carbapenemase production was considered positive when the 
Phoenix system results showed “carbapenemase producer,” 
“class A carbapenemase producer,” “class B carbapenemase 
producer,” or “class D carbapenemase producer”; otherwise, it 
was considered negative. In terms of CPO classification, “car-
bapenemase producer” were considered as “not classified.” In 
addition, “class A carbapenemase producer,” “class B carba-
penemase producer,” and “class D carbapenemase producer” 
were considered as correctly classified when corresponding to 
the same class determined by conventional PCR, but were con-
sidered as incorrectly classified when corresponding to a differ-
ent class. 
Table 1. Oligonucleotide sequences of the primers used in this study
Primer name Target gene                      Nucleotide sequence Product size Reference
KPC-F blaKPC- GTCACTGTATCGCCGTCTAGTTC 909 26
KPC-R TGGTGGGCCAATAGATGATT
NDM-F blaNDM- GCCCAATATTATGCACCCGG 738 26
NDM-R CTCATCACGATCATGCTGGC
IMP-F blaIMP- AAGGCGTTTATGTTCATACTTCG 605 26
IMP-R TTTAACCGCCTGCTCTAATGTAA
VIM-F blaVIM- ATCATGGCTATTGCGAGTCC 749 27
VIM-R ACGACTGAGCGATTTGTGTG
OXA-F blaOXA-48-like AGCAAAGGAATGGCAAGAAA 845 28
OXA-R TCATCAAGTTCAACCCAACC
Table 2. AST results for Enterobacteriaceae
Antimicrobial
N isolates Phoenix system vs BMD, N (%)
S I R EA CA mE ME VME
Imipenem 212 2 143 358 (87.5) 357 (87.2) 45 (11.0) 7 (1.7) 0 (0)
Meropenem 231 7 132 342 (83.6) 370 (90.5) 28 (6.7) 10 (2.4) 1 (0.2)
Ertapenem 195 4 188 402 (98.3) 387 (94.6) 21 (5.1) 1 (0.2) 0 (0)
Ceftazidime 125 10 253 402 (98.3) 388 (94.9) 18 (4.4) 1 (0.2) 2 (0.5)
Ceftazidime/Avibactam 317 -   82 358 (87.5) 399 (97.6) 0 (0) 6 (1.5) 4 (0.9)
Abbreviations: AST, antimicrobial susceptibility testing; BMD, broth microdilution; EA, essential agreement; CA, categorical agreement; S, susceptible; I, in-
termediate; R, resistant; mE, minor error; ME, major error; VME, very major error.
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RESULTS
Enterobacteriaceae
Table 2 and Fig. 1 detail the AST results obtained using the BD 
Phoenix NMIC-500 panel and BMD with 409 clinical Entero-
bacteriaceae isolates. Most antimicrobials showed high CA and 
EA rates (>90%), except for imipenem, which showed a CA 
rate of 87.2%. In addition, only seven VME were observed, and 
the ME rates were 3%. 
GNFB
Table 3 and Fig. 2 detail the CAs, EAs, as well as mE, ME, and 
Table 3. AST results for glucose-non-fermenting gram-negative bacilli
Antimicrobial
Isolates (N) Phoenix system vs BMD, N (%)
S I R EA CA mE ME VME
Imipenem 4 0 34 36 (87.8) 38 (92.7) 2 (4.8) 1 (2.4) 0 (0)
Meropenem 2 1 36 40 (97.6) 39 (95.1) 2 (4.8) 0 (0) 0 (0)
Ceftazidime 1 0 37 41 (100) 38 (92.7) 3 (7.3) 0 (0) 0 (0)
Ceftazidime/Avibactam 0 0 21 21 (100) 21 (100) 0 (0) 0 (0) 0 (0)
Abbreviations: AST, antimicrobial susceptibility testing; BMD, broth microdilution; EA, essential agreement; CA, categorical agreement; S, susceptible; I, in-
termediate; R, resistant; mE, minor error; ME, major error; VME, very major error.
Fig. 1. Enterobacteriaceae MICs determined using broth microdilution and the BD Phoenix NMIC-500 panel. The MICs of meropenem (A), 
imipenem (B), ertapenem (C), ceftazidime (D), and ceftazidime-avibactam (E) were determined using 409 clinical isolates; dark gray indi-
cates identical agreement, and light gray indicates 2-fold difference between the BMD and NMIC-500 panel MICs. Dotted lines indicate the 
clinical breakpoints for each antimicrobial.
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VME numbers and rates for 41 clinical P. aeruginosa and A. bau-
mannii isolates. High agreement was observed between the re-
sults of BD Phoenix NMIC-500 panel and BMD. The CA and EA 
rates were all >90%, ranging from 92.7% to 100% and from 
97.6% to 100%, respectively, except for the EA of imipenem, 
which was 87.8%. Only one ME was identified for imipenem. 
CPO detection 
Table 4 details the CPO results obtained by PCR/sequencing 
and the BD Phoenix NMIC-500 panel. The rates of correct iden-
tification in carbapenemase production were 98.6% (70/71) for 
the class A carbapenemase-producers, 98.1% (101/103) for 
class B carbapenemase-producers, and 96.7% (59/61) for class 
D carbapenemase producers. The rates for correct classification 
were 73.6% (184/250) in the carbapenemase-producers. In the 
15 dual carbapenemase producers, 86.7% (13/15) were posi-
tive for carbapenemase production; however, the Phoenix sys-
tem could identify only one class of carbapenemase between 
the two types of carbapenemases or could not identify the class 
of carbapenemase. In addition, most carbapenemase-nonpro-
ducers (99.5%, 199/200) were negative for carbapenemase 
production.
DISCUSSION
The carbapenem MICs obtained using the BD Phoenix NMIC-
500 panel were higher than those obtained by BMD. The ME 
rates were slightly elevated, while VME was identified in only 
1.5% (7/450) of all isolates. These results indicate high sensitiv-
ity of carbapenem resistance detection. Consistent with our re-
sults, Menozzi et al. [22] evaluated the previous AST panel of 
BD Phoenix system with identical bacterial species and reported 
that the EA and CA were 87.6% and 98.7%, 96.0% and 99.5%, 
and 95.8% and 98.7% for imipenem, meropenem, and ceftazi-
dime, respectively, with clinical Enterobacteriaceae isolates, and 
93.5% and 94.8%, 90.0% and 98.7%, and 94.8% and 97.4% 
for imipenem, meropenem, and ceftazidime, respectively, with 
clinical GNFB isolates.
The BD Phoenix NMIC-500 panel showed high performance 
for CPO detection. Consistent with our results, Thomson et al. 
[23] evaluated the BD Phoenix CPO Detect system (BD Diag-
nostic Systems), which is an AST panel similar to the BD Phoe-
nix NMIC-500 panel, and showed that 97.3% (107/110) of class 
A carbapenemases, 95.6% (87/91) of class B carbapenemases, 
and 100% (35/35) of class D carbapenemases were positively 
identified. However, although the dual carbapenemase produc-
ers were positively identified, the system could not classify them. 
In the same study, Carba NP (bioMérieux, St. Louis, MO, USA) 
could positively identify 98.2% of class A, 98.9% of class B, and 
94.3% of class D producers, as well as the dual carbapenemase 
producers. Although Carba NP showed high CPO detection per-
formance, this kit required extra time for AST. In addition, Carba 
NP requires a chromogenic medium, which exhibits different 
shades of color that could be challenging for laboratory staff to 
interpret. In contrast, the BD Phoenix NMIC-500 panel was eas-
ier to interpret as it does not require a chromogenic medium, 
and CPO detection was more rapid. 
The BD Phoenix NMIC-500 panel could identify carbapene-
mase production in 86.7% (13/15) of the dual carbapenemase-
producing isolates; however, it could identify only one class of 
Fig. 2. MICs of glucose-non-fermenting gram-negative bacilli determined using the broth microdilution method and the BD Phoenix NMIC-
500 panel. The MICs of meropenem (A), imipenem (B), and ceftazidime (C) was determined with 20 Acinetobacter and 21 P. aeruginosa 
isolates. In the case of ceftazidime-avibactam (D), only P. aeruginosa was assessed. Dark gray indicates identical agreement, and light gray 
indicates 2-fold difference between the MICs determined using BMD and the BD Phoenix NMIC-500 panel. Dotted lines indicate the clini-
cal breakpoints for each antimicrobial.
Abbreviations: MIC, minimum inhibitory concentration; BMD, broth microdilution.
A B C D
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Table 4. CPO detection using the Phoenix system and PCR+sequencing
Class of carbapenemase − species N isolates
CPO detected using the Phoenix system, N (%)
Carbapenemase production Carbapenemase classification
Positive Negative Correct Incorrect Not classified
Class A carbapenemase producers* 71 70 (98.6) 1 (1.4) 58 (81.7) 1 (1.4) 11 (15.5)
K. pneumoniae 51 50 (98.0) 1 (2.0) 42 (82.4) 0 (0) 8 (15.7)
E. coli 13 13 (100) 0 (0) 11 (84.6) 1 (7.7) 1 (7.7)
Enterobacter species 5 5 (100) 0 (0) 3 (60.0) 0 (0) 2 (40.0)
Citrobacter freundii 2 2 (100) 0 (0) 2 (100) 0 (0) 0 (0)
Class B carbapenemase producers 103 101 (98.1) 2 (1.9) 74 (71.8) 10 (9.7) 17 (16.5)
NDM 53 53 (100) 0 (0) 49 (92.5) 0 (0) 4 (7.5)
K. pneumoniae 23 23 (100) 0 (0) 21 (91.3) 0 (0) 2 (8.7)
E. coli 13 13 (100) 0 (0) 13 (100) 0 (0) 0 (0)
Enterobacter species 11 11 (100) 0 (0) 9 (81.8) 0 (0) 2 (18.2)
Citrobacter freundii 5 5 (100) 0 (0) 5 (100) 0 (0) 0 (0)
K. oxytoca 1 1 (100) 0 (0) 1 (100) 0 (0) 0 (0)
VIM 29 27 (93.1) 2 (6.9) 17 (58.6) 8 (27.6) 2 (6.9)
Enterobacter species 18 16 (88.9) 2 (10.1) 8 (44.4) 7 (38.9) 1 (5.6)
K. pneumoniae 8 8 (100) 0 (0) 8 (100) 0 (0) 0 (0)
E. coli 2 2 (100) 0 (0) 1 (50) 1 (50) 0 (0)
Citrobacter freundii 1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100)
IMP 21 21 (100) 0 (0) 8 (38.1) 2 (9.5) 11 (52.4)
P. aeruginosa 21 21 (100) 0 (0) 8 (38.1) 2 (9.5) 11 (52.4)
Class D carbapenemase producer 61 59 (96.7) 2 (3.3) 50 (82.0) 3 (4.9) 6 (9.8)
OXA-48-like 41 40 (97.6) 2 (4.9) 35 (85.4) 0 (0) 4 (9.8)
K. pneumoniae 37 36 (97.3) 1 (2.7) 32 (86.5) 0 (0) 4 (10.8)
E. coli 4 3 (75.0) 1 (25.0) 3 (75.0) 0 (0) 0 (0)
OXA-23 20 20 (100) 0 (0) 15 (75.0) 3 (15.0) 2 (10.0)
A. baumannii 20 20 (100) 0 (0) 15 (75.0) 3 (15.0) 2 (10.0)
Dual carbapenemase producer† 15 13 (86.7) 2 (13.3) 2 (13.3) 5 (33.3) 6 (40.0)
K. pneumoniae 7 6 (85.7) 1 (14.3) 0 (0) 5 (71.4) 1 (14.3)
Enterobacter species 2 2 (100) 0 (0) 2 (100) 0 (0) 0 (0)
Raoutella species 5 4 (80.0) 1 (20.0) 0 (0) 0 (0) 4 (80.0)
Citrobacter freundii 1 1 (100) 0 (0) 0 (0) 0 (0) 1 (100)
Subtotal of carbapenemase producers 250 243 (97.2) 7 (2.8) 184 (73.6) 19 (7.6) 40 (16.0)
Carbapenemase nonproducers 200 1 (0.5) 199 (99.5) - - -
E. coli 101 1 (1.0) 100 (99.0) - - -
K. pneumoniae 99 0 (0) 99 (100) - - -
*All Class A carbapenemase producers were KPC-producers; †The 15 dual carbapenemase producers included seven KPC and NDM coproducers (one K. 
pneumoniae, one Citrobacter freundii, and five Raoutella species), six NDM and OXA-48-like coproducing K. pneumoniae, one IMP and VIM coproducing 
Enterobacter species, and one NDM and VIM coproducing Enterobacter species.
Abbreviations: CPO, carbapenemase producing organisms; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-beta-lactamase; VIM, 
Verona integron-borne metallo-beta-lactamase; IMP, imipenemase; OXA, oxacillinase.
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carbapenemase out of two in dual carbapenemase producers. 
Moreover, the remaining two isolates, which were correctly iden-
tified by the BD Phoenix NMIC-500 panel, harbored two car-
bapenemase genes within the same class. Thomson et al. [23] 
also suggested that most dual carbapenemase producers were 
not correctly identified using the BD Phoenix CPO Detect and 
that this should be improved in subsequent panels. 
Ceftazidime-avibactam is the most active compound tested 
against KPC-producing isolates. Ceftazidime-avibactam was in-
troduced to treat infections caused by KPC-producers, and its 
ability has been demonstrated [24, 25]. Our results showed that 
ceftazidime-avibactam could suppress the action of 94.4% (67/ 
71) of KPC-producing isolates. Thus, ceftazidime-avibactam has 
potential to combat carbapenem-resistant Enterobacteriaceae.
A limitation of this study was that carbapenemase-non-pro-
ducing carbapenem-resistant organisms were not included to 
evaluate the accuracy of CPO detection. This should be further 
investigated to confirm the accuracy of this panel.
In conclusion, the BD Phoenix NMIC-500 panel showed prom-
ising ability for MIC determination and CPO detection in a large 
number of clinical GNB isolates. The BD Phoenix NMIC-500 
panel showed high agreement with conventional methods. By 
including carbapenemase detection and ceftazidime/avibactam 
MIC determination in routine AST, the BD Phoenix NMIC-500 
panel offers valuable support for clinical studies examining dif-
ferent therapeutic strategies for infections caused by such or-
ganisms. This capability, in conjunction with good infection con-
trol, can help ensure that medical institutions are at minimal risk 
of a CPO pandemic.
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